By Gilang Cahya 
In a significant breakthrough that could reshape our understanding of cancer development, an international consortium of researchers, spearheaded by the University of California San Diego (UC San Diego), has pinpointed a likely microbial offender behind the disturbing surge in early-onset colorectal cancer: a potent bacterial toxin known as colibactin. This discovery offers a crucial piece of the puzzle in explaining a modern medical mystery that has baffled scientists and clinicians alike.
Colibactin, a harmful substance produced by specific strains of Escherichia coli bacteria commonly residing in the human colon and rectum, possesses the alarming capability to directly damage and alter DNA. The new research, meticulously detailed in the prestigious scientific journal Nature on April 23, reveals that exposure to colibactin, particularly during early childhood, leaves a distinct and recognizable genetic signature on the DNA of colon cells. This molecular imprint, the study suggests, significantly elevates the risk of developing colorectal cancer at a much younger age, often before an individual reaches 50.
Decoding the Genetic Fingerprint of Colibactin
The comprehensive study analyzed a substantial dataset comprising 981 colorectal cancer genomes. These genomes were drawn from patients exhibiting both early-onset (diagnosed before age 50) and late-onset (diagnosed after age 70) forms of the disease, spanning across 11 countries with diverse levels of colorectal cancer incidence. The findings were striking: the specific patterns of DNA mutations associated with colibactin exposure were found to be an astonishing 3.3 times more prevalent in early-onset cases, especially in adults under the age of 40, when compared to their older counterparts. Furthermore, these characteristic mutation patterns were disproportionately concentrated in countries that already report a high incidence of early-onset colorectal cancer, providing strong geographical correlation.
"These mutation patterns act as a kind of historical record embedded within the genome, and they compellingly point to early-life exposure to colibactin as a primary driving force behind the development of early-onset disease," stated Ludmil Alexandrov, the study’s senior author. Professor Alexandrov, a distinguished figure in bioengineering and cellular and molecular medicine at UC San Diego, also holds significant affiliations with the UC San Diego Moores Cancer Center and serves as Deputy Director of the Sanford Stem Cell Fitness and Space Medicine Center. His lab has been at the forefront of investigating mutational signatures for years.
While prior investigations, including earlier work by Alexandrov’s own research group, had identified colibactin-related mutations in approximately 10 to 15 percent of all colorectal cancer cases, those studies often either focused on late-onset disease or did not differentiate between early- and late-onset presentations. This latest, expansive study marks the first time researchers have definitively demonstrated a substantial enrichment of colibactin-induced mutations specifically within the cohort of early-onset colorectal cancer patients.
A Growing Epidemic Among the Young
The implications of this discovery are profoundly concerning. Colorectal cancer, historically considered a disease primarily affecting older adults, has seen a dramatic and escalating rise in incidence among younger populations in at least 27 countries worldwide. The rate of new cases in adults under the age of 50 has roughly doubled every decade for the past two decades. Projections based on current trends suggest that colorectal cancer could become the leading cause of cancer-related mortality among young adults by the year 2030, a grim outlook that underscores the urgency of understanding its underlying causes.
Until the advent of this new research, the reasons behind this alarming surge have remained largely elusive. Young adults diagnosed with colorectal cancer frequently lack a discernible family history of the disease and present with few of the traditionally recognized risk factors, such as obesity, hypertension, or a sedentary lifestyle. This lack of clear etiology has fueled speculation among the scientific community regarding the potential role of previously unidentified environmental exposures or microbial influences – a void that this groundbreaking study directly addresses.
The Genesis of Early-Onset Cancer: A Childhood Imprint
"When we embarked on this project, our initial intention was not to specifically focus on early-onset colorectal cancer," explained Marcos Díaz-Gay, a former postdoctoral researcher in Alexandrov’s lab and a co-first author of the study. "Our original objective was to conduct a global analysis of colorectal cancer patterns to understand the disparities in incidence rates between different countries. However, as we delved deeper into the data, one of the most surprising and significant findings that emerged was the remarkable frequency with which colibactin-related mutations appeared in the early-onset cases."
The team’s meticulous analysis indicates that colibactin’s detrimental effects commence at a very early stage of life. By employing advanced molecular timing techniques to analyze each identified mutational signature, the researchers have established that colibactin-associated mutations arise early in the tumor development process. This aligns with previous findings suggesting that such mutations can occur within the first decade of life. The study further reveals that colibactin-related mutations are responsible for approximately 15% of what are known as "APC driver mutations" – some of the earliest and most critical genetic alterations that directly fuel cancer development in colorectal cancer.
"If an individual acquires one of these critical driver mutations by the time they are 10 years old," Professor Alexandrov elaborated, "they could be decades ahead of the typical timeline for developing colorectal cancer, potentially experiencing a diagnosis at age 40 instead of the more common age of 60."
In essence, the research suggests that colibactin-producing bacteria may quietly colonize the colons of children, initiating subtle yet significant molecular changes in their DNA. These early alterations could, over time, lay the groundwork for the development of colorectal cancer long before any outward symptoms become apparent.
While the findings provide robust support for this hypothesis, Professor Alexandrov stressed the need for continued rigorous research to definitively establish causality.
Building on a Foundation of Mutational Signature Research
This pivotal work, which is a component of the international Cancer Grand Challenges team named Mutographs and funded by Cancer Research UK, represents the latest milestone in a sustained and expanding body of research spearheaded by Alexandrov, Díaz-Gay, and their collaborators over the past several years. Their specialized expertise lies in deciphering the intricate patterns of DNA mutations induced by various environmental exposures, including ultraviolet radiation and bacterial toxins, as well as lifestyle choices such as smoking and alcohol consumption. Each of these factors leaves a unique and identifiable genetic fingerprint within the genome – a distinct mutational signature that can serve as a crucial clue in pinpointing the origins of specific cancers.
As part of a long-term, collaborative effort involving UC San Diego, the International Agency for Research on Cancer (IARC) in France, and the Wellcome Sanger Institute in the United Kingdom, facilitated by Cancer Grand Challenges funding, the Mutographs team has successfully elucidated the underlying mutational processes responsible for esophageal, kidney, and head and neck cancers globally. This latest breakthrough concerning colorectal cancer further broadens the international understanding of cancer etiology through the sophisticated lens of mutational signature analysis.
By systematically cataloging these complex mutational patterns across thousands of cancer genomes, the researchers have been actively working to identify novel causes of cancer that may have previously eluded detection.
"Not every environmental factor or human behavior we investigate leaves a discernible mark on our genome," Professor Alexandrov remarked. "However, we have observed that colibactin is indeed one of those agents capable of doing so. In this particular instance, its genetic imprint appears to be strongly associated with colorectal cancers that manifest in young adults."
Unanswered Questions and Future Directions
The team’s latest discovery inevitably raises a cascade of new and critical questions that demand further investigation. How are children being exposed to colibactin-producing bacteria in the first place? What preventive measures can be implemented to mitigate or eliminate this exposure? Are specific environmental conditions, dietary habits, or lifestyle choices more conducive to the proliferation and toxin production of these bacteria? And crucially, how can individuals determine if they have already acquired these damaging mutations?
The research team is actively exploring several promising hypotheses. They are conducting further in-depth examinations of the correlation between colibactin exposure and the risk of early-onset colorectal cancer. Additionally, they are investigating the potential of probiotics as a safe and effective means to eliminate harmful bacterial strains from the gut microbiome. A significant area of focus is the development of early detection tests that can analyze stool samples for the presence of colibactin-related mutations, offering a non-invasive approach to identify individuals at higher risk.
Meanwhile, the Mutographs team continues its global pursuit of identifying cancer-linked mutational signatures. The recent Nature study also revealed that colorectal cancers originating from specific countries – notably Argentina, Brazil, Colombia, Russia, and Thailand – exhibited an increased prevalence of certain mutational signatures. This finding strongly suggests that local environmental exposures may also play a significant role in contributing to cancer risk within particular regions.
"It is entirely plausible that different countries harbor distinct, as-yet-unidentified causes of cancer," stated Díaz-Gay, who is now launching a new phase of research in his recently established laboratory at the Spanish National Cancer Research Center (CNIO) in Madrid, Spain. "This realization opens up the exciting potential for developing targeted, region-specific prevention strategies tailored to local risk factors."
Professor Alexandrov highlighted a broader, more profound implication of this research: that a significant proportion of cancers may, in fact, originate from environmental or microbial exposures encountered much earlier in life, often long before any clinical diagnosis is made.
"This discovery fundamentally reshapes how we conceptualize cancer," he concluded. "It suggests that cancer development may not solely be a consequence of processes occurring in adulthood. Instead, it could be profoundly influenced by events that transpire in early life, perhaps even within the first few years of a person’s existence. Sustained and robust investment in this line of research will be absolutely critical in the global endeavor to prevent and effectively treat cancer before it becomes too late."
